Meeting
2022 ASCO Annual Meeting
Mebendazole in recurrent glioblastoma: Results of a phase 2 randomized study.
Authors
Nandini Sharrel Menon
Tata Memorial Centre, Mumbai, India
Nandini Sharrel Menon , Abhishek Chatterjee , Raees Tonse , Amit Choudhary , Abhishek Mahajan , Ameya Puranik , Epari Sridhar , Shruti Pathak , Monica Jadhav , Zoya Peelay , Rutuja Walavalkar , Hemanth Kumar , Madala Ravi Krishna , Arun Chandrasekharan , Nikhil Pande , Tejpal Gupta , Shripad Dinanath Banavali , Rakesh Jalali , Vijay Maruti Patil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
CTRI/2018/01/011542
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2029)
DOI
10.1200/JCO.2022.40.16_suppl.2029
Abstract #
2029
Poster Bd #
367
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
First Author: Yazmin Odia
Poster
2018 ASCO Annual Meeting
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
First Author: Martin J. Van Den Bent
Poster
2023 ASCO Annual Meeting
Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.
First Author: David D. Tran
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen